USD 24.43
↓ -0.49 (-1.97%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ARVN | -2.0 | -12.0 | -5.7 | -4.6 | -24.4 | 20.3 | -70.6 | -19.9 | 52.2 | 52.2 |
| S&P 500 | -0.7 | -1.2 | 1.6 | 6.5 | 11.3 | 31.2 | 26.1 | 89.3 | 189.3 | 33342.1 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ARVN |
| name | Arvinas, Inc. |
| price | 24.43 |
| changes percentage | -1.97 |
| change | -0.49 |
| day low | 24.41 |
| day high | 25.10 |
| year high | 53.08 |
| year low | 20.28 |
| market cap | 1678661033 |
| price avg 50 | 25.82 |
| price avg 200 | 32.00 |
| exchange | NASDAQ |
| volume | 32314 |
| avg volume | 544001 |
| open | 25.07 |
| previous close | 24.92 |
| eps | -4.79 |
| pe | -5.10 |
| earnings announcement | 2025-02-25T05:00:00.000+0000 |
| shares outstanding | 68713100 |
| timestamp | 2024-11-15 14:35:41 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001655759 | |||
| revenue | 78500000 | 131400000 | -40.26 |
| gross profit | 71800000 | 123200001 | -41.72 |
| gross profit ratio | 0.91 | 0.94 | -2.45 |
| research and development expenses | 379700000 | 315000000 | 20.54 |
| operating expenses | 480000000 | 394600000 | 21.64 |
| interest income | 38800000 | 12200000 | 218.03 |
| interest expense | 0 | 12000000 | -100.00 |
| ebitda | -394800000 | -256899999 | -53.68 |
| ebitdaratio | -5.03 | -2.0 | -151.08 |
| operating income | -401500000 | -263200000 | -52.55 |
| operating income ratio | -5.11 | -2.0 | -155.34 |
| net income | -367300000 | -271900000 | -35.09 |
| net income ratio | -4.68 | -2.07 | -126.12 |
| eps | -6.62 | -5.11 | -29.55 |
Revenue Growth: revenue increased to 78 million in 2023 from 131 million in 2022 representing a change of -40.26%. This indicates a sales growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 380 million in 2023 from 315 million in 2022 representing a change of 20.54%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -395 million in 2023 from -257 million in 2022 representing a change of -53.68%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -402 million in 2023 from -263 million in 2022 representing a change of -52.55%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -367 million in 2023 from -272 million in 2022 representing a change of -35.09%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Gross Profit: Gross Profit decreased to 72 million in 2023 from 123 million in 2022 representing a change of -41.72%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 480 million in 2023 from 395 million in 2022 representing a change of 21.64%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -6.62 in 2023 from -6.62 in 2022 representing a change of -29.55%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001655759 | |||
| revenue | 102400000 | 76500000 | 33.86 |
| gross profit | 102400000 | 74800000 | 36.90 |
| gross profit ratio | 1 | 0.98 | 2.27 |
| research and development expenses | 86900000 | 93700000 | -7.26 |
| operating expenses | 162700000 | 123300000 | 31.95 |
| interest income | 14300000 | 13600000 | 5.15 |
| interest expense | 0 | 0 | NaN |
| ebitda | -60300000 | -46800000 | -28.85 |
| ebitdaratio | -0.59 | -0.61 | 3.74 |
| operating income | -60300000 | -48500000 | -24.33 |
| operating income ratio | -0.59 | -0.63 | 7.12 |
| net income | -49200000 | -35200000 | -39.77 |
| net income ratio | -0.48 | -0.46 | -4.42 |
| eps | -0.68 | -0.49 | -38.78 |
Revenue Growth: revenue decreased to 102 million in 2024Q3 from 76 million in 2024Q2 representing a change of 33.86%. This indicates a sales shrinking, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 87 million in 2024Q3 from 94 million in 2024Q2 representing a change of -7.26%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 163 million in 2024Q3 from 123 million in 2024Q2 representing a change of 31.95%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -0.68 in 2024Q3 from -0.68 in 2024Q2 representing a change of -38.78%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Gross Profit: Gross Profit increased to 102 million in 2024Q3 from 75 million in 2024Q2 representing a change of 36.9%. This indicates a sales profitability growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -60 million in 2024Q3 from -47 million in 2024Q2 representing a change of -28.85%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -60 million in 2024Q3 from -48 million in 2024Q2 representing a change of -24.33%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -49 million in 2024Q3 from -35 million in 2024Q2 representing a change of -39.77%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001655759 | |||
| total assets | 1304600000 | 1268800000 | 2.82 |
| total liabilities | 644600000 | 703900000 | -8.42 |
| total equity | 660000000 | 564900000 | 16.83 |
| cash and cash equivalents | 311700000 | 81300000 | 283.39 |
| short term investments | 949300000 | 1124000000 | -15.54 |
| long term investments | 0 | 0 | NaN |
| total current assets | 1280200000 | 1240200000 | 3.23 |
| total non current assets | 24400000 | 28600000 | -14.69 |
| total current liabilities | 257100000 | 295100000 | -12.88 |
| total non current liabilities | 387500000 | 408800000 | -5.21 |
| common stock | 100000 | 100000 | 0.00 |
| retained earnings | -1332700000 | -965400000 | -38.05 |
| total debt | 3200000 | 5500000 | -41.82 |
Total Assets: Total Assets increased to 1,305 million in 2023 from 1,269 million in 2022 representing a change of 2.82%. Suggesting a growth in asset holdings.
Total Liabilities: Total Liabilities decreased to 645 million in 2023 from 704 million in 2022 representing a change of -8.42%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 660 million in 2023 from 565 million in 2022 representing a change of 16.83%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 312 million in 2023 from 81 million in 2022 representing a change of 283.39%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 1,280 million in 2023 from 1,240 million in 2022 representing a change of 3.23%. This indicates a better liquidity position.
Total Current Liabilities: Total Current Liabilities decreased to 257 million in 2023 from 295 million in 2022 representing a change of -12.88%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 3 million in 2023 from 6 million in 2022 representing a change of -41.82%. This indicates a reduction in overall debt burden.
Short Term Investments: Short Term Investments decreased to 949 million in 2023 from 1,124 million in 2022 representing a change of -15.54%. This indicates a decrease in short-term investment holdings.
Retained Earnings: Retained Earnings decreased to -1,333 million in 2023 from -965 million in 2022 representing a change of -38.05%. This indicates an accumulated losses.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001655759 | |||
| total assets | 1167100000 | 1279600000 | -8.79 |
| total liabilities | 581100000 | 679400000 | -14.47 |
| total equity | 586000000 | 600200000 | -2.37 |
| cash and cash equivalents | 85200000 | 160300000 | -46.85 |
| short term investments | 1036400000 | 1073900000 | -3.49 |
| long term investments | 0 | 0 | NaN |
| total current assets | 1149500000 | 1256700000 | -8.53 |
| total non current assets | 17600000 | 22899999 | -23.14 |
| total current liabilities | 275900000 | 347200000 | -20.54 |
| total non current liabilities | 305200000 | 332200000 | -8.13 |
| common stock | 100000 | 100000 | 0.00 |
| retained earnings | -1486500000 | -1437300000 | -3.42 |
| total debt | 1500000 | 2300000 | -34.78 |
Total Assets: Total Assets decreased to 1,167 million in 2024Q3 from 1,280 million in 2024Q2 representing a change of -8.79%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 586 million in 2024Q3 from 600 million in 2024Q2 representing a change of -2.37%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 85 million in 2024Q3 from 160 million in 2024Q2 representing a change of -46.85%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 1,036 million in 2024Q3 from 1,074 million in 2024Q2 representing a change of -3.49%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 1,150 million in 2024Q3 from 1,257 million in 2024Q2 representing a change of -8.53%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -1,486 million in 2024Q3 from -1,437 million in 2024Q2 representing a change of -3.42%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 581 million in 2024Q3 from 679 million in 2024Q2 representing a change of -14.47%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 276 million in 2024Q3 from 347 million in 2024Q2 representing a change of -20.54%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 2 million in 2024Q3 from 2 million in 2024Q2 representing a change of -34.78%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001655759 | |||
| net change in cash | 230400000 | -26000000 | 986.15 |
| operating cash flow | -347800000 | -273500000 | -27.17 |
| free cash flow | -350700000 | -280300000 | -25.12 |
| capital expenditure | -2900000 | -6800000 | 57.35 |
| depreciation and amortization | 6700000 | 8200000 | -18.29 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 71600000 | 75500000 | -5.17 |
| accounts payables | 17300000 | 20200000 | -14.36 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 400000 | -100.00 |
| investments in property plant and equipment | -2900000 | -6800000 | 57.35 |
| net cash used for investing activites | 203500000 | 242800000 | -16.19 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 387200000 | 4700000 | 8,138.30 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 374700000 | 4700000 | 7,872.34 |
| cash at end of period | 317200000 | 86800000 | 265.44 |
| accounts receivables | 800000 | 14000000 | -94.29 |
| cash at beginning of period | 86800000 | 112800000 | -23.05 |
Net Change in Cash: Net Change in Cash increased to 230 million in 2023 from -26 million in 2022 representing a change of 986.15%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Stock-Based Compensation: Stock-Based Compensation decreased to 72 million in 2023 from 76 million in 2022 representing a change of -5.17%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 17 million in 2023 from 20 million in 2022 representing a change of -14.36%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to 1 million in 2023 from 14 million in 2022 representing a change of -94.29%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to -348 million in 2023 from -274 million in 2022 representing a change of -27.17%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -351 million in 2023 from -280 million in 2022 representing a change of -25.12%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -3 million in 2023 from -7 million in 2022 representing a change of 57.35%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001655759 | |||
| operating cash flow | -128000000 | 50300000 | -354.47 |
| free cash flow | -128700000 | 49600000 | -359.48 |
| capital expenditure | -700000 | -700000 | 0.00 |
| depreciation and amortization | 1600000 | 1700000 | -5.88 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 24700000 | 21600000 | 14.35 |
| accounts receivables | -4800000 | -2900000 | -65.52 |
| accounts payables | -2400000 | 1800000 | -233.33 |
| inventory | 0 | 0 | NaN |
| acquisitions net | -100000 | 100000 | -200.00 |
| investments in property plant and equipment | -700000 | -700000 | 0.00 |
| net cash used for investing activites | 50500000 | 13100000 | 285.50 |
| debt repayment | 0 | -100000 | 100.00 |
| common stock issued | -5300000 | 3500000 | -251.43 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 2400000 | 3400000 | -29.41 |
| net change in cash | -75100000 | 66800000 | -212.43 |
| cash at end of period | 85200000 | 160300000 | -46.85 |
| cash at beginning of period | 160300000 | 93500000 | 71.44 |
Net Change in Cash: Net Change in Cash decreased to -75 million in 2024Q3 from 67 million in 2024Q2 representing a change of -212.43%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -128 million in 2024Q3 from 50 million in 2024Q2 representing a change of -354.47%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -129 million in 2024Q3 from 50 million in 2024Q2 representing a change of -359.48%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 25 million in 2024Q3 from 22 million in 2024Q2 representing a change of 14.35%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 2 million in 2024Q3 from 2 million in 2024Q2 representing a change of -233.33%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to -5 million in 2024Q3 from -3 million in 2024Q2 representing a change of -65.52%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 1.41 | 2.47 | -42.73 |
| net income per share | -6.62 | -5.11 | -29.49 |
| operating cash flow per share | -6.27 | -5.14 | -21.90 |
| free cash flow per share | -6.32 | -5.27 | -19.93 |
| cash per share | 22.72 | 22.66 | 0.29 |
| book value per share | 11.89 | 10.62 | 11.99 |
| tangible book value per share | 11.89 | 10.62 | 11.99 |
| shareholders equity per share | 11.89 | 10.62 | 11.99 |
| interest debt per share | 0.01 | 0.28 | -94.82 |
| market cap | 2284380000 | 1819972000 | 25.52 |
| enterprise value | 1975880000 | 1744172000 | 13.28 |
| pe ratio | -6.22 | -6.69 | 7.08 |
| price to sales ratio | 29.1 | 13.85 | 110.10 |
| pocfratio | -6.57 | -6.65 | 1.30 |
| pfcf ratio | -6.51 | -6.49 | -0.32 |
| pb ratio | 3.46 | 3.22 | 7.43 |
| ptb ratio | 3.46 | 3.22 | 7.43 |
| ev to sales | 25.17 | 13.27 | 89.63 |
| enterprise value over ebitda | -5.0 | -6.79 | 26.28 |
| ev to operating cash flow | -5.68 | -6.38 | 10.92 |
| ev to free cash flow | -5.63 | -6.22 | 9.46 |
| earnings yield | -0.16 | -0.15 | -7.62 |
| free cash flow yield | -0.15 | -0.15 | 0.32 |
| debt to equity | 0.0 | 0.0 | -75.55 |
| debt to assets | 0.0 | 0.0 | -72.21 |
| net debt to ebitda | 0.78 | 0.3 | 164.83 |
| current ratio | 4.98 | 4.2 | 18.48 |
| interest coverage | 0 | -21.93 | 100.00 |
| income quality | 0.95 | 0.97 | -2.19 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 1.28 | 0.61 | 110.92 |
| research and ddevelopement to revenue | 4.84 | 2.4 | 101.77 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.01 | -0.02 | 66.46 |
| capex to revenue | 0.04 | 0.05 | -28.61 |
| capex to depreciation | 0.43 | 0.83 | -47.81 |
| stock based compensation to revenue | 0.91 | 0.57 | 58.74 |
| graham number | 42.08 | 34.94 | 20.42 |
| roic | -0.61 | -0.5 | -21.28 |
| return on tangible assets | -0.28 | -0.21 | -31.38 |
| graham net net | 11.2 | 9.59 | 16.83 |
| working capital | 1023100000 | 945100000 | 8.25 |
| tangible asset value | 660000000 | 564900000 | 16.83 |
| net current asset value | 635600000 | 536300000 | 18.52 |
| invested capital | 1037100000 | 962900000 | 7.71 |
| average receivables | 7600000 | 16850000 | -54.90 |
| average payables | 11750000 | 18500000 | -36.49 |
| average inventory | 2750000 | 5000000 | -45.00 |
| days sales outstanding | 33.48 | 22.22 | 50.65 |
| days payables outstanding | 969.7 | 253.72 | 282.19 |
| days of inventory on hand | 0 | 244.82 | -100.00 |
| receivables turnover | 10.9 | 16.43 | -33.62 |
| payables turnover | 0.38 | 1.44 | -73.84 |
| inventory turnover | 0 | 1.49 | -100.00 |
| roe | -0.56 | -0.48 | -15.62 |
| capex per share | 0.05 | 0.13 | -59.12 |
ROE: Return on Equity (ROE) decreased to -0.56 on 2023-12-31 from -0.48 on 2022-12-31, representing a change of -15.62%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 4.98 on 2023-12-31 from 4.20 on 2022-12-31, representing a change of 18.48%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -6.22 on 2023-12-31 from -6.69 on 2022-12-31, representing a change of 7.08%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2023-12-31 from 0.00 on 2022-12-31, representing a change of -75.55%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| ARVN | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 1.42 | 1.06 | 33.48 |
| net income per share | -0.68 | -0.49 | -39.39 |
| operating cash flow per share | -1.78 | 0.7 | -353.77 |
| free cash flow per share | -1.79 | 0.69 | -358.76 |
| cash per share | 15.56 | 17.17 | -9.38 |
| book value per share | 8.13 | 8.35 | -2.64 |
| tangible book value per share | 8.13 | 8.35 | -2.64 |
| shareholders equity per share | 8.13 | 8.35 | -2.64 |
| interest debt per share | 0.02 | 0.01 | 99.45 |
| market cap | 1775823000 | 1867962000 | -4.93 |
| enterprise value | 1692123000 | 1709962000 | -1.04 |
| pe ratio | -9.02 | -13.27 | 31.98 |
| price to sales ratio | 17.34 | 24.42 | -28.98 |
| pocfratio | -13.87 | 37.14 | -137.36 |
| pfcf ratio | -13.8 | 37.66 | -136.64 |
| pb ratio | 3.03 | 3.11 | -2.63 |
| ptb ratio | 3.03 | 3.11 | -2.63 |
| ev to sales | 16.52 | 22.35 | -26.07 |
| enterprise value over ebitda | -28.06 | -36.54 | 23.20 |
| ev to operating cash flow | -13.22 | 34.0 | -138.89 |
| ev to free cash flow | -13.15 | 34.48 | -138.14 |
| earnings yield | -0.03 | -0.02 | -47.02 |
| free cash flow yield | -0.07 | 0.03 | -372.94 |
| debt to equity | 0.0 | 0.0 | 104.85 |
| debt to assets | 0.0 | 0.0 | 119.28 |
| net debt to ebitda | 1.39 | 3.38 | -58.89 |
| current ratio | 4.17 | 3.62 | 15.11 |
| interest coverage | 0 | 0 | NaN |
| income quality | 2.6 | -1.43 | 282.06 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.74 | 0.41 | 80.92 |
| research and ddevelopement to revenue | 0.85 | 1.22 | -30.71 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.01 | 0.01 | -139.30 |
| capex to revenue | 0.01 | 0.01 | -25.29 |
| capex to depreciation | 0.44 | 0.41 | 6.25 |
| stock based compensation to revenue | 0.24 | 0.28 | -14.57 |
| graham number | 11.17 | 9.59 | 16.49 |
| roic | -0.1 | -0.08 | -28.03 |
| return on tangible assets | -0.04 | -0.03 | -53.25 |
| graham net net | 7.65 | 7.82 | -2.18 |
| working capital | 873600000 | 909500000 | -3.95 |
| tangible asset value | 586000000 | 600200000 | -2.37 |
| net current asset value | 568400000 | 577300000 | -1.54 |
| invested capital | 881400000 | 920800000 | -4.28 |
| average receivables | 12400000 | 8550000 | 45.03 |
| average payables | 20450000 | 20500000 | -0.24 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 13.01 | 11.76 | 10.57 |
| days payables outstanding | 0 | 1228.24 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 6.92 | 7.65 | -9.56 |
| payables turnover | 0 | 0.07 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.08 | -0.06 | -43.16 |
| capex per share | 0.01 | 0.01 | -0.28 |
ROE: Return on Equity (ROE) decreased to -0.08 on 2024-09-30 Q3 from -0.06 on 2024-06-30 Q2, representing a change of -43.16%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 4.17 on 2024-09-30 Q3 from 3.62 on 2024-06-30 Q2, representing a change of 15.11%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -9.02 on 2024-09-30 Q3 from -13.27 on 2024-06-30 Q2, representing a change of 31.98%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2024-09-30 Q3 from 0.00 on 2024-06-30 Q2, representing a change of 104.85%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is -17.66 which is lower than current price 24.43, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-07 09:05:00
- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside's Suprachoroidal Space (SCS ® ) Delivery Platform - ALPHARETTA, Ga., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the Company's Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical Co., Ltd.
Sentiment: Negative
Publish Date: 2024-11-04 07:00:00
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:
Sentiment: Positive
Publish Date: 2024-10-30 15:43:05
Arvinas, Inc. (NASDAQ:ARVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jeff Ball - Chief Financial Officer John Houston - Chief Executive Officer, President and Chairperson Noah Berkowitz - Chief Medical Officer Andrew Sake - Chief Financial Officer Angela Cacace - Chief Scientific Officer Conference Call Participants Akash Tewari - Jefferies Brad Canino - Stifel Etzer Darout - BMO Capital Markets Ellie Merle - UBS Derek Archila - Wells Fargo Li Watsek - Cantor Ted Tenthoff - Bipolar Sandler Tazeen Ahmad - Bank of America Michael Schmidt - Guggenheim Tyler Van Buren - TD Cowen Jonathan Miller - Evercore ISI Yigal Nochomovitz - Citigroup Matthew Biegler - Oppenheimer Operator Thank you for standing by. At this time, I'd like to welcome everyone to Arvinas Third Quarter 2024 Earnings Call.
Sentiment: Negative
Publish Date: 2024-10-30 09:16:27
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to loss of $1.18 per share a year ago.
Sentiment: Negative
Publish Date: 2024-10-30 07:00:00
– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented at San Antonio Breast Cancer Symposium in December 2024 – – Recently presented new preclinical data for the PROTAC LRRK2 degrader ARV-102 demonstrating that LRRK2 degradation affects biomarkers in the CSF – - $1.1 billion in cash, cash equivalents and marketable securities as of Sept. 30, 2024 - – Company to host conference call today at 8:00 a.m.
Sentiment: Positive
Publish Date: 2024-10-22 16:05:00
NEW HAVEN, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that employees from 16 states participated in the Company's third annual “Arvinas Impact Day,” a company-wide day of service where employees joined forces to give back to their communities, engaging in various volunteer activities that made a tangible difference across the Greater New Haven area and beyond.
Sentiment: Negative
Publish Date: 2024-10-21 07:00:00
NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2024 financial results and provide a corporate update during a live webcast on Wednesday, October 30, 2024, at 8:00 a.m. ET.
Sentiment: Negative
Publish Date: 2024-08-29 07:00:00
NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
